معرفی
Jennifer Maynard is a Professor of Chemical Engineering at the University of Texas at Austin, holding the Z. D. Bonner Professorship and the Clair and Peter Buenz Endowed Chair within the Cockrell School of Engineering. Her work bridges chemical engineering, immunology, and microbiology to develop novel biomedical solutions.
Education:
- B.A. in Human Biology, Stanford University (1996)
- Ph.D. in Chemical Engineering, University of Texas at Austin (2002)
- NIH Postdoctoral Fellow, Microbiology & Immunology, Stanford University (2002-2004)
Research Focus: Dr. Maynard pioneers protein therapeutics and vaccines targeting infectious diseases through precision protein engineering. Her lab designs molecules that either directly disrupt pathogens or enhance immune responses, with emphasis on kinetics control and tissue-specific targeting. Key methodologies include structural analysis, biophysical characterization, and in vitro/in vivo validation, yielding breakthroughs in pertussis and SARS-CoV-2 interventions.
Publication Trends: Recent work (2019-2022) demonstrates dual expertise in infectious disease therapeutics and cancer immunotherapy. Her team leverages structural biology to engineer conditionally active antibodies for tumor microenvironments while developing neutralizing antibodies against bacterial toxins. SARS-CoV-2 research focuses on spike protein dynamics for vaccine design, revealing novel epitopes through conformational analysis.
Awards & Recognition:
- National Academy of Inventors Senior Member (2023)
- Fellow of AIMBE (2017)
- UT Emerging Inventor of the Year (2015)
- Bill & Melinda Gates Grand Challenge Awards (2009, 2016)
- Texas Exes Teaching Award (2012)
- Packard Fellowship (2005)
Mentorship & Teaching: Dr. Maynard trains graduate students in protein engineering while teaching core chemical engineering courses including Material and Energy Balances, Thermodynamics, and Bioengineering. Her lab operates at the chemistry-biology interface, combining recombinant protein expression with advanced immunological assays to develop next-generation therapeutics against evolving pathogens.
